In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Novartis AG

www.novartis.com

Latest From Novartis AG

Keeping Track: Approval Of First Intranasal Naloxone Copycat Highlights Otherwise Generic Week

The latest drug development news and highlights from our US FDA Performance Tracker. 
US FDA Performance Tracker Drug Review

Finance Watch: Hatteras Nearly Halfway To $200m Goal For New Early-Stage VC Fund

Private Company Edition: General Partner Clay Thorp says the venture capital firm's longtime focus on seed and early-stage investments is unchanged and bolstered by market fundamentals. Also, Talaris and insitro each raised $100m Series A rounds, plus other financings.

Financing StartUps and SMEs

Finance Watch: Turning Point Launches IPO, Stock Rises 60% On First Day

Public Company Edition: Turning Point's offering priced at $18 and its stock closed at $28.90. Also, Achaogen's bankruptcy reflects difficult antibacterial market, Ophthotech's name change follows strategy shift, and Gilead lays off 150 sales reps. Plus, cell and gene therapy FOPOs flourish.

Financing Business Strategies

J&J's Spravato's Star Power Rises While Zytiga's Sets

With Spravato's launch underway, J&J reports that 800 sites have been certified to administer the depression drug. Newer drugs drove pharma sales in the first quarter, while US sales of Zytiga declined 55% due to generic competition. 

Companies Commercial
See All

Company Information

Advertisement
Advertisement
UsernamePublicRestriction

Register